Emerging approaches to dyslipidemia management beyond LDL-c
VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.
This 3-minute education provides a summary of recently presented scientific data, recorded during the VBWG meeting at ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.
Eliot Brinton, MD, is Director of Atherometabolic Research at the Utah Foundation for Biomedical Research, and President of the Utah Lipid Center, in Salt Lake City, UT, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.